Division of Urology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium.
Prostate cancer cells have an exquisite tropism for bone, which clinically translates into the highest rate of bone metastases amongst male cancers. Although in the latest years there has been an active development of new "bone targeted" therapies, modern diagnostic techniques for bone metastases still relies mostly on (99m)Tc bone scanning (BS) and plain X-ray. BS dramatically lacks specificity and sensitivity. Recent publications using modern imaging technologies have clearly pinpointed that BS grossly underestimates the true prevalence of bone metastasis. In addition BS does not allow tumour measurement and is, therefore, not appropriate to monitor response to therapy. This might be extremely important in patients harbouring high-risk localized disease that are eventually candidate for local therapy. Here we reviewed what are the emerging imaging strategies that are likely to supplant BS and to what extent they can be used in the clinic already.
Written by:
Tombal B, Lecouvet F. Are you the author?
Reference: Adv Urol. 2012;2012:893193.
doi: 10.1155/2012/893193
PubMed Abstract
PMID: 22013439
UroToday.com Prostate Cancer Section
